MG4101 Plus Rituximab Including Lymphodepletion in Patient With r/r NHL B-cell Origin
Clinical trial NCT03778619 · UNKNOWN
Trial details
- NCT number
- NCT03778619
- Sponsor
- GC Cell Corporation
- Status
- UNKNOWN
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-11-28
- Primary completion
- 2020-04-20
- Enrollment
- 9
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.